Autotransfusion Systems Market

Autotransfusion Systems Market Outlook (2023 to 2033)

The global autotransfusion systems market is valued at US$ 315.4 million in 2023 and is expected to expand at 4% CAGR to reach US$ 466.8 million by the end of 2033.

An autotransfusion is a procedure in which a patient receives a transfusion of their blood rather than stored allogenic (separate-donor) blood. The patient's blood is collected and reinfused using autotransfusion devices. These systems are crucial to cell salvage procedures, which allow autologous blood transfusions to lower the risk of infections brought on by allogeneic blood transfusions.

Autotransfusion tools are used in invasive procedures such as heart surgeries, orthopaedic surgeries, neurological surgeries, obstetrical and gynaecological surgeries, etc. Systems can be divided into three categories according to their usability: postoperative systems, intraoperative systems, and dual-mode systems. The rising cases related to surgeries worldwide are boosting the sales of autotransfusion systems.

• For instance, around 18 million deaths take place each year due to cardiovascular disorders worldwide, according to WHO.

Such statistics can help to understand the rate of surgeries taking place worldwide. Global demand for autotransfusion systems is also increasing due to the rapidly rising rate of the ageing population, the growing prevalence of chronic disorders, and the need for advanced blood management systems.

Autotransfusion products & accessories are two segments of the market. Global demand for autotransfusion products is predicted to progress at a CAGR of 4.5% during the next 10 years. Due to their effectiveness in blood transfusion, autotransfusion products are becoming more and more popular in both developed and developing nations.

Furthermore, it is anticipated that greater connectivity, transfusion report generations, technological developments for better clinical results, and improved flexibility are fuelling sales growth. The growing rate of blood transfusion and increasing demand for proper blood management are boosting the sales of autotransfusion accessories. The demand for autotransfusion accessories is expected to increase at a CAGR of 3% during the forecast period.

Report Attributes	Details
Autotransfusion Systems Market Size (2023E)	US$ 315.4 Million
Forecasted Market Value (2033F)	US$ 466.8 Million
Global Market Growth Rate (2023 to 2033)	4% CAGR
China Market Growth Rate (2023 to 2033)	4% CAGR
Japan Market Growth Rate (2023 to 2033)	4% CAGR
Germany Market Growth Rate (2023 to 2033)	4% CAGR
Canada Market Growth Rate (2023 to 2033)	3.5% CAGR
Key Companies Profiled	Atrium Medical Corporation (A Part of Getinge Group) Becton, Dickinson and Company Beijing ZKSK Technology Co., Ltd. Braile Biomédica Fresenius Medical Care AG & Co. KGaA Gen World Medical Devices Haemonetics Corporation Livanova PLC Medtronic PLC Redax

What is Expected to Aid Providers of Autotransfusion Systems Gain Market Share?

“Strong Shift towards Autologous Blood Transfusion”

Allogeneic blood infusions are quite likely to have negative effects such as increased mortality, tumour recurrence, post-operative infections, acute lung injuries, and post-operative cardiac failures. Examples include the prevalence of transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI), which are estimated to be 1% and 0.1% of transfusion cases in the United States, respectively, following numerous patient-based research.

As a result, shifting preference in favour of cell salvage can significantly minimize the need for allogeneic blood transfusion, hence reducing the likelihood of unfavourable side effects, which subsequently is boosting the autotransfusion system demand.

“Rapidly Increasing Number of Surgeries”

Blood transfusions and intra and postoperative cell salvage are crucial components of blood conservation throughout every surgical treatment. Growing cases of high-bleeding procedures and the emphasis on minimizing problems from allogeneic transfusions are also anticipated to fuel the growth of the autotransfusion systems market over the forecast period.

• For instance, the American Academy of Orthopaedic Surgeons (AAOS) and the Agency for Healthcare Research and Quality (AHRQ) estimate that every year in the United States, approximately 700,000 knee replacements and about 450,000 hip replacements are carried out.
• The University of Alabama revealed in a 2021 article that 320,000 coronary artery bypass grafting surgeries were carried out in the United States in the year 2020.
• The World Health Organization (WHO) 2022 study states that worldwide, crashes and traffic accidents result in 1.3 million fatalities per year. An additional 20 to 50 million people sustain non-fatal injuries, and many of them suffered physical impairment.

One of the main causes of disabilities and mortality worldwide is traffic accidents. Also, due to the increasing trend of physical activities, children and adults are more likely to experience sports-related injuries. The growing awareness of intraoperative and postoperative blood salvage is generating new opportunities in the market for autotransfusion systems, says Fact.MR, a market research and competitive intelligence provider.

Which Factors are Hampering the Sales of Autotransfusion Products?

“Surging Demand for Minimally-invasive Surgeries and Increasing Use of Hemostatic Devices”

Patients are gradually turning away from invasive procedures in favour of minimally-invasive ones. During the projection period, the use of minimally-invasive surgical procedures is anticipated to rise due to several variables, including shorter hospital stays, lower costs, quicker patient recoveries, and more patient comfort. As less blood is lost during minimally-invasive surgeries, it is hoped that the increasing use of less-invasive surgery would eventually lessen the need for blood conservation or allogeneic transfer.

• For instance, the German Heart Surgery Report estimates that in 2020, almost 55.2% of isolated mitral valve surgeries were carried out by minimally-invasive access, which represents a significant increase from the year prior.

The adoption of hemostatic products to stop significant blood loss is also anticipated to impede the sales of products for autotransfusion systems.

Country-wise Analysis

Why is the United States Considered a Profitable Market for Autotransfusion System Manufacturers?

“Presence of Key Market Players and Advanced Healthcare Systems”

The United States is expected to dominate the North American autotransfusion systems market, throughout the forecast period. The presence of major autotransfusion system companies, the high volume of surgeries performed in the country, and the well-established healthcare infrastructure are some of the aspects driving the demand for autotransfusion products.

Furthermore, favourable government programs and knowledge of autotransfusion due to a scarcity of allogenic blood in the nation are some of the factors anticipated to spur sales growth. A sophisticated healthcare sector and benevolent healthcare policies in the United States are supporting sales growth.

• The American National Red Cross estimates that 36,000 units of red blood cells are required in the country per day.

According to statistics, this country's rising disposable income and growing blood donation deficiency both contribute to the United States autotransfusion systems market growth.

How is Demand for Autotransfusion Systems Evolving in Germany?

“Increasing Surgical Cases Related to Trauma & Accidents”

Favourable health reimbursement policies, rising cases related to trauma and accident surgeries, and robust advancement in the medical sector are expected to increase the sales of autotransfusion devices in Germany. The rising government funding for healthcare R&D is also expected to support sales growth.

Growing accident and trauma cases, increasing rate of sports-related injuries, and rising ageing population who are more prone to experience orthopedic surgeries are fuelling the demand for autotransfusion systems in the nation. Sales of autotransfusion systems in Germany are predicted to evolve at a CAGR of 4% during the forecast period.

What is Supporting the Development of Autotransfusion Systems in South Korea?

“Growing Awareness of and Advancements in Blood Management Systems”

Rapidly developing blood management systems in South Korea are expected to boost the sales of autotransfusion systems. The demand for blood surpasses the supply despite Korea having a greater blood donation rate than high-income countries (5.04% vs. 3.15%), according to the WHO. This is brought on by the ageing and expanding recipient population, the declining birth rate, and the scarcity of young donors.

Blood transfusion is a vital aspect of any surgery to save lives. Thus, the increasing awareness for blood management, rising government initiatives for blood donation and management, and growing R&D activities on blood transfusion are boosting the demand for autotransfusion systems.

Category-wise Analysis

For Which Disorders are Autotransfusion Systems Widely Used?

“Rising Prevalence of Cardiovascular Disorders”

Based on application, the autotransfusion systems are segmented into cardiovascular surgeries, orthopedic surgeries, obstetrics & gynecological surgeries, and neurological surgeries. It is predicted that the demand for autotransfusion devices from cardiovascular surgeries will increase at a rapid pace during the forecast period, due to the rising prevalence of cardiovascular disorders worldwide.

Rising cases related to heart disorders such as coronary artery bypass grafting (CABG), implantable cardioverter-defibrillator (ICD) & pacemaker implantations, heart transplantations, and valve replacement are increasing the chances of surgeries, which subsequently increases the demand for autotransfusion systems. Also, the rising prevalence of orthopedic surgeries is expected to increase demand for autotransfusion devices at a high pace during the forecast period.

Why Do Hospitals Account for High Demand for Autotransfusion Systems?

“Hospitals First Preference of Patients to Get Advanced & Effective Treatment”

Demand for autotransfusion systems from hospitals is expected to evolve at a rapid pace from 2023 to 2033. Rising cases related to surgeries, increasing prevalence of chronic disorders resulting in operations, and advancements in technologies and infrastructure are attracting patients to visit hospitals to get advanced treatment procedures.

Thus, the high intake of patients in hospitals is boosting the sales of autotransfusion devices. However, it is projected that in the coming years, specialty clinics will increasingly use intraoperative and postoperative cell salvage, particularly in developed regions, which would increase demand for autotransfusion systems.

Competitive Landscape

Some of the key players in the autotransfusion systems market are Atrium Medical Corporation (A Part of Getinge Group), LivaNova, Becton, Dickinson and Company, Beijing ZKSK Technology Co., Ltd, Haemonetics, Braile Biomédica, and Fresenius Medical Care AG & Co. KGaA.

Several autotransfusion system providers are adopting various marketing strategies such as collaborations, partnerships, local supply, improving product standards, and more to earn more profits.

• In the autotransfusion systems market, LivaNova has a dominant position. The cardiovascular product section of LivaNova provides advanced autotransfusion systems. Due to its expertise and dedication to the study of novel solutions, the company is regarded as a global leader in autotransfusion. Since 2010, doctors have received support from LivaNova's most cutting-edge, intuitive, and potent ATS system, XTRA, which combines cutting-edge technological features with user-friendliness and potent performance. Over a million patients have benefited from XTRA, which has lowered the hazards of allogeneic transfusion and shortened hospital stays.
• One of the top brands in the autotransfusion systems industry is Fresenius. The company's Fresenius Kabi subsidiary provides a robust line of autotransfusion devices. For recycling blood intra and post or during cardiac, orthopedic, or vascular surgeries, Fresenius Kabi developed CATSmart, a novel continuous red cell separation technique based on continuous flow technology. The continuous flow technique used by CATSmart, the only autotransfusion device on the market, ensures quick access to red blood cells (RBCs) at any time with consistent quality.
• Haemonetics has established a strong position for itself in the autotransfusion systems market. The company offers a wide range of products for whole blood cells, plasma, and blood. During medium to high blood loss procedures, such as cardiac, orthopedic, trauma, transplant, vascular, and OBGYN surgeries, hospitals can recover and distribute back a patient's high-quality blood with the use of the company's Cell Saver Elite device.

Key Segments of Autotransfusion Systems Industry Research

• By Type :

  • Autotransfusion Products
  • Autotransfusion Accessories

• By Application :

  • Cardiovascular Surgeries
  • Orthopedic Surgeries
  • Obstetrics & Gynecological Surgeries
  • Neurological Surgeries

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • MEA